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Axon pathﬁnding and synapse formation are essential processes for nervous system development and function. The assembly of
myelinated ﬁbres and nodes of Ranvier is mediated by a number of cell adhesion molecules of the immunoglobulin superfamily
including neurofascin, encoded by the NFASC gene, and its alternative isoforms Nfasc186 and Nfasc140 (located in the axonal
membrane at the node of Ranvier) and Nfasc155 (a glial component of the paranodal axoglial junction). We identiﬁed 10
individuals from six unrelated families, exhibiting a neurodevelopmental disorder characterized with a spectrum of central (intel-
lectual disability, developmental delay, motor impairment, speech difﬁculties) and peripheral (early onset demyelinating neur-
opathy) neurological involvement, who were found by exome or genome sequencing to carry one frameshift and four different
homozygous non-synonymous variants in NFASC. Expression studies using immunostaining-based techniques identiﬁed absent
expression of the Nfasc155 isoform as a consequence of the frameshift variant and a signiﬁcant reduction of expression was also
observed in association with two non-synonymous variants affecting the ﬁbronectin type III domain. Cell aggregation studies
revealed a severely impaired Nfasc155-CNTN1/CASPR1 complex interaction as a result of the identiﬁed variants.
Immunoﬂuorescence staining of myelinated ﬁbres from two affected individuals showed a severe loss of myelinated ﬁbres and
abnormalities in the paranodal junction morphology. Our results establish that recessive variants affecting the Nfasc155 isoform
can affect the formation of paranodal axoglial junctions at the nodes of Ranvier. The genetic disease caused by biallelic NFASC
variants includes neurodevelopmental impairment and a spectrum of central and peripheral demyelination as part of its core
clinical phenotype. Our ﬁndings support possible overlapping molecular mechanisms of paranodal damage at peripheral nerves
in both the immune-mediated and the genetic disease, but the observation of prominent central neurological involvement in NFASC
biallelic variant carriers highlights the importance of this gene in human brain development and function.
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Introduction
In the vertebrate nervous system, myelinated ﬁbres
allow rapid nerve impulse transmission because of the
ensheathment of their axons by specialized glial cells to
form the multilamellar myelin sheath. Also, voltage-gated
sodium channels (Nav) are clustered at the nodes of
Ranvier further facilitating the rapid conduction of nerve
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impulses in the vertebrate brain and peripheral nerves
(Ghosh et al., 2018). Neurofascin protein isoforms
Nfasc186 and Nfasc155 are splice variants encoded by
the NFASC gene (MIM: 609145) and belong to the L1
family of immunoglobulin cell adhesion molecules, which
play a critical role in the assembly of the node of Ranvier
(Ghosh et al., 2018). Nfasc155 is a glial isoform abun-
dantly expressed in myelinating Schwann cells and pre-
dominantly enriched at the paranodal sites, acting as a
ligand for the axonal contactin-1 (CNTN1)/contactin-
associated protein-1 (CASPR1) complex. Nfasc186 rep-
resents the axonal isoform expressed at the node of
Ranvier membranes where it is involved in the long-
term maintenance and stability of Nav channels (Fig. 1)
(Sherman et al., 2005; Taylor et al., 2018).
Autoantibodies against Nfasc186 and Nfasc155 are asso-
ciated with severe forms of chronic inﬂammatory demye-
linating polyneuropathy (CIDP) and cause an immune-
mediated nodo-paranodopathy (Querol et al., 2017;
Vallat et al., 2018) further demonstrating that these pro-
teins play a crucial role in conduction. Biallelic variants
in gliomedin (GLDN) and CNTNAP1 encoding essential
components of the nodes of Ranvier and paranodes, re-
spectively, lead to inherited nodo-paranodopathies, a dis-
tinct disease entity among peripheral neuropathies
(Maluenda et al., 2016). Smigiel et al. (2018) report the
identiﬁcation of a homozygous truncating NFASC muta-
tion affecting the ﬁbronectin type III domain, speciﬁc to
the Nfasc155 isoform in a child presenting with a very
severe neurodevelopmental disorder resembling spinal
muscular atrophy, while Monfrini et al. (2019) report a
homozygous missense mutation in a case with autosomal
recessive ataxia and a demyelinating neuropathy.
Importantly, a human Mendelian disease caused by
NFASC variants has been reported only in these two
single individuals to date.
Here, we describe 10 individuals from six families car-
rying homozygous non-synonymous or frameshift variants
in NFASC. Phenotypic analysis of affected individuals
revealed, in all cases, global developmental delay and
weakness with variable features of chronic demyelinating
neuropathy in some cases. For some of the identiﬁed
variants, we compared surface expression of the disease
variant and wild-type Nfasc155 isoforms. We also tested
the capability of variant proteins to interact with other
partner proteins at paranodal sites, including gliomedin
and the CNTN1/CASPR1 complex. Abnormalities of
paranodal junction were identiﬁed by immunoﬂuorescence
analyses of myelinated ﬁbres from skin samples of two
affected individuals carrying homozygous variants in
NFASC. Our results link biallelic variants in NFASC
isoforms at glial cells to defects in the paranodal axoglial
junctions and phenotypes that range from variable
neurodevelopmental impairment to weakness, central
hypomyelination, and peripheral chronic demyelinating
neuropathy.
Materials and methods
This study was approved by local institutional IRB/ethical
review boards of all participating centres, and written in-
formed consent was obtained prior to genetic testing from
all the families involved. Clinical details were obtained
through medical ﬁle review and clinical examination.
Genomic DNA was extracted from peripheral blood samples
according to standard procedures. Whole exome sequencing
(WES) was performed as described elsewhere (Mencacci
et al., 2016), and our bioinformatics ﬁltering strategy
included screening for only exonic and donor/acceptor spli-
cing variants. In accordance with the pedigree and phenotype,
priority was given to rare variants [50.01% in public data-
bases, including 1000 Genomes project, NHLBI Exome
Variant Server, Complete Genomics 69, and Exome
Aggregation Consortium (ExAC v0.2)] that were ﬁtting a
recessive (homozygous or compound heterozygous) or a de
novo model and/or variants in genes previously linked to
neuropathy, intellectual disability and other neurological dis-
orders. Other families were recruited through GeneMatcher
(https://genematcher.org/).
Molecular biology
NFASC missense constructs were cDNA synthesized by
GenScript into pCMV-3Tag-4A by replacing the coding
sequence for these inserts via BamHI and XhoI (NEB),
giving rise to pCMV_Nfasc186[WT], pCMV_Nfasc186
[N130D], pCMV_Nfasc186[R359P], pCMV_Nfasc186
[P694T], pCMV_Nfasc186[S820P], pCMV_Nfasc155[WT],
pCMV_Nfasc155[N124D], pCMV_Nfasc155[R370P], pCMV_
Nfasc155[P705T], pCMV_Nfasc155[S831P] and pCMV_N
fasc155[P939Ter].
To generate pCMV_Nfasc155[P939Ter], the respective variant
was introduced with the QuickChange Site-Directed Mutagenesis
Kit (Agilent Technologies). A Myc epitope was then inserted
before the stop codon into pCMV_Nfasc155[P939Ter] using
site-directed mutagenesis kit with primers: 50-GAACAAAAACT
CATCTCAGAAGAGGATCTGtgattggatacactctcaaat-03 and 50-
CAGATCCTCTTCTGAGATGAGTTTTTGTTCTGATCCCA-
TTTGGATGCTCAG-30.
Cell assays
Human embryonic kidney (HEK) cells were transfected with
Nfasc155 or Nfasc186 variants using JetPEI (Polyplus-trans-
fection). After 48 h, cells were incubated for 20min at 37C
with rabbit antibodies against Nfasc186 (D6G60; Cell
Signaling Technology) or Nfasc155 (D7B6O; Cell Signaling
Technology) diluted 1/50 in Opti-MEMTM or with 1 mg of
gliomedin-Fc (Devaux, 2012) diluted in Opti-MEMTM
(ThermoFisher Scientiﬁc). Cells were then washed in phos-
phate-buffered saline (PBS), ﬁxed with 2% paraformaldehyde
in PBS and blocked with blocking solution (5% ﬁsh skin gel-
atin containing, 0.1% TritonTM X-100 in PBS). HEK cells
were incubated with a mouse anti-Myc antibody (Roche; 1/
200) for 1 h, then incubated with Alexa conjugated secondary
antibodies (1/500; Jackson ImmunoResearch) for 30min.
Coverslips were washed three times in PBS, stained with
DAPI, and mounted with Mowiol plus 2% DABCO. In
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some experiments, HEK cells were co-transfected with GFP
and Nfasc155 variants. In those experiments, cells were ﬁxed
and revealed with a mouse anti-Myc antibody.
Immunostainings were examined using an ApoTome ﬂuores-
cence microscope (ApoTome, AxioObserver and AxioCam
MRm, Carl Zeiss MicroImaging GmbH). Digital images
were manipulated into ﬁgures with CorelDRAW and Corel
Photo-Paint.
Cell aggregation assay
N2A cells were plated in 6-well plates at a density of 500 000
cells/well and were transiently transfected using JetPEI
(Polyplus-transfection) with Nfasc155 and ptdTomato-N1
(Clontech), CNTN1/CASPR1 and peGFP-N1 (Clontech), or
peGFP-N1 alone. The day after, cells were trypsinized
using 0.05% trypsin in PBS and suspended in 1ml serum
Figure 1 Schematic diagram showing the different domains of a myelinated axon. The axonal region around the node of Ranvier is
expanded to show the different axonal domains: the node of Ranvier where voltage-gated Na + channels (Nav1.6 and Nav1.1) are expressed, the
paranode where the myelin is attached to the axon, and the juxtaparanode where most voltage-gated K + channels (KCNQ2/3 and Kv1) are
located. Each of these domains is characterized by the expression of specific cell adhesion molecules; at the nodes Nfasc186 binds gliomedin
(GLDN) and NrCAM, which are secreted by Schwann cells in the nodal gap lumen, at the paranode Nfasc155 forms a complex with CNTN1/
CASPR1 to form the septate-like junctions, and at the juxtaparanode the CNTN2/CASPR2 complex enables the sequestration of Kv1 channels.
Adapted and modified from Arancibia-Carcamo and Attwell (2014).
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free Opti-MEMTM medium (ThermoFisher Scientiﬁc). Cells
were mixed together in a 1:1 ratio (400 000 cells/ml), and
then agitated at 100 rpm for 2 h at 37C. Cell suspension
(100ml) was then mounted between slides and coverslip, and
was immediately observed using a ﬂuorescence microscope
with 5 objective. The number of cells in mixed aggregates
was evaluated in 10 ﬁelds. Aggregates were deﬁned as clusters
of at least four cells including red and green cells. The four
experiments were performed for each condition.
Immunoblots
HEK cells were transfected with Nfasc155 constructs for 24h,
then the cells were washed in PBS and solubilized on ice for
15min in 1% TritonTM X-100, 140mM NaCl, 20mM Tris-
HCl, pH 7.4 containing protease inhibitors. Proteins (50mg)
were loaded on 7.5% SDS-PAGE gels, transferred, and immu-
noblotted with a mouse antibody against Myc (1:2000) or a
mouse antibody against -tubulin (1:2000; MABT205; Merck).
Immunoreactivity was revealed using peroxidase-coupled sec-
ondary antibodies (1:5000; Jackson ImmunoResearch) and
BM chemiluminescence kit (Roche). The integrated densities
of each protein band were measured with ImageLab software
(Bio-Rad).
Molecular modelling
Wild-type and mutated NFASC isoforms were built from
structure PDB ID 3P3Y (Supplementary material). Each pro-
tein was placed in a cubic box and minimized. A water layer
of 0.8 nm and Na+ ions to neutralize the system were added,
and a second minimization was performed. In all cases we
used AMBER99SB-ILDN (Lindorff-Larsen et al., 2010) force
ﬁeld and simple point charge water. In all systems we per-
formed NVT [constant number of atoms, volume and tempera-
ture (canonical ensemble)] and NPT [constant number of
atoms, pressure and temperature (isothermal-isobaric ensem-
ble)] equilibrations for 100 ps, followed by 360ns NPT
production run at 300K. The temperature was controlled
with a modiﬁed Berendsen thermostat (Bussi et al., 2007),
and the pressure with an isotropic Parrinello-Rahman, at
100 kPa. The iteration time step was set to 2 fs, with the
Verlet integrator and LINCS (Hess, 2008) constraint. We
used periodic boundary conditions. Conﬁgurations were
sampled every 10 ps. All the simulations and their analyses
were run as implemented in the GROMACS package (Pronk
et al., 2013).
Immunofluorescence staining of
patient skin
Skin samples (3mm) were taken using a disposable punch after
intradermal injection of lidocaine from the leg and forearm of
Patient 1, and from leg, thigh and ﬁngertip of Patient 3, and of
a 5-year-old male with a suspected indifference to pain as con-
trol. Specimens were ﬁxed overnight in Zamboni solution
(American Mastertech), cryoprotected in 20% sucrose in PBS
and sent in a refrigerated package to the laboratory of Telese.
The skin samples were cut into 50-mm thick sections using a
freezing slide microtome (Leica 2000R). Free-ﬂoating sections
were processed for indirect immunoﬂuorescence using
antibodies to stain nerve ﬁbres, myelin and vascular structures.
To visualize nodal and paranodal architecture, rabbit antibo-
dies against panNeurofascin (1:2000, courtesy of Prof P.
Brophy), Nfasc186 (1:800, Cell Signaling Technology) or
CASPR1 (1:1000, Abcam) were used. Axon and myelin were
visualized with primary mouse antibodies against protein gene
product 9.5 (PGP; AbD Serotec; 1:800), myelin basic protein
(MBP; Santa Cruz Biotechnology; 1:800), or collagen IV
(COLIV; Chemicon; 1:800) or a rabbit antibody against PGP
(Biogenesis; 1:400). Species-speciﬁc secondary antibodies
coupled with cyanine 2 and cyanine 3 ﬂuorophores were
used to visualize the structures of interest. ULEX Europaeus
agglutinin 1 coupled with cyanine 5 was used to visualize
blood vessels and epidermis. Skin sections were mounted on
coverslips with agar, dehydrated in alcohol, clariﬁed in methyl-
salicylate and ﬁnally mounted in DPX. Digital images were
acquired using a non-laser confocal microscope (Apotome;
Zeiss).
Co-expression network analysis
Co-expression network analysis was used to investigate the
function of NFASC across the human central and peripheral
nervous system. This analysis was performed by using GTEx
V6 gene expression data (Carithers et al., 2015) to generate
co-expression networks for each of the 13 brain tissues and
tibial nerve RNA-seq data included within the GTEx study.
The raw FPKM (fragments per kilobase of transcript per mil-
lion mapped reads) values were corrected for known batch
effects, age at death, sex and post-mortem interval, as well
as unknown effects. The unknown effects were detected with
the surrogate variable analysis (SVA) R Package (Leek and
Storey, 2007) and correction was performed using ComBat
(Johnson et al., 2007). The resulting residuals were used to
create a signed network using the blockwiseConsensusModules
R function from the WGCNA R package (Langfelder and
Horvath, 2008) for each of the 14 tissues. Next, the modules
obtained in each of the 14 networks were assigned to cell
types using the userListEnrichment R function implemented
in the WGCNA R package, which measures enrichment be-
tween module-assigned genes and deﬁned brain-related lists
using a hypergeometric test. The same approach was used to
annotate modules with Gene Ontology, REACTOME
(Fabregat et al., 2018) and KEGG (Kanehisa et al., 2016)
terms.
Data availability
The data that support the ﬁndings of this study are available
from the corresponding author, upon reasonable request.
Results
Identification of the NFASC variants
Biallelic NFASC variants were independently identiﬁed as the
primary candidate genetic cause for the phenotype observed
in the six families described herein (Fig. 2 and Table 1).
WES carried out in Family 1 (Fig. 2) revealed a homozygous
variant in NFASC (chr1:204948591C4A). This variant
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Figure 2 Pedigrees, Sanger sequencing, multiple-sequence alignment of NFASC and clinico-radiological natural history of
patients. (A) Pedigrees of the six families carrying biallelic NFASC mutations and Sanger sequencing electropherograms confirming the mutations.
(B) Facial pictures of Patients 1–3; note the facial hypomimia present in all cases, the muscle weakness and inability to hold his neck in Patient 1
carrying the p.P694T variant, and the tongue protrusion in Patients 2 and 3 carrying the frameshift mutation p.P939Ter. (C) MRIs of Patients 1–3
and 10 showing loss of cerebral white matter and atrophic changes of corpus callosum and brainstem: T2-weighted coronal MRI showing enlarged
lateral ventricles in Patient 1 indicative of cortical volume loss (top left). T1-weighted sagittal MRI-sequence of Proband 2 displaying thin corpus
callosum as well as cortical volume loss (top right). Axial T2-weighted sequence in Patient 3 showing progressive loss of cerebral white and grey
matter (bottom left). T1-weighted sagittal MRI-sequence of Proband 10 displaying thin corpus callosum as well as cortical volume loss (bottom right).
(D) In silico modelling of the 3D structure of the p.N130D and p.R359P variants. In the top left image [wild-type (WT) protein], a hydrogen bonding
interaction with the side chain of glutamine 46 is visible. The residue of lysine 49 is distant from the point of mutation and forms a salt bridge with
the carbonyl moiety of residue tyrosine 416. In addition, a weaker hydrophobic (cation-) interaction forms between the side chains of lysine 49
and tyrosine 416 (red dashes, connecting the charged nitrogen atom with the centre of the phenyl ring). The top right image shows the different
hydrogen bonding network formed in the mutant: the mutated aspartate residue forms three hydrogen bonding interactions, two involving its side
chain and the side chain of residue lysine 49, and the third between its amino moiety and the side chain of residue glutamine 46. No interactions
are visible between residues lysine 46 and tyrosine 416 that are further apart (6 A˚) and with an unsuitable geometry. In the bottom left image
(wild-type protein), a strong hydrogen bonding network connects residues aspartate 352, arginine 370 and aspartate 402 positioned on three
different b-strands. The absence of the arginine residue in the mutant (bottom right) impedes the formation of the hydrogen bonding network,
distancing the three b-strands. (E) A schematic representation of Nfasc155 and Nfasc186 showing the position of all NFASC variants. (F) Inter-
species alignment performed with Clustal Omega shows the complete conservation down to invertebrates of the amino acid residues affected by
the substitutions.
Neurofascin variants in neurodevelopment BRAIN 2019: 0; 1–17 | 7
D
ow
nloaded from
 https://academ
ic.oup.com
/brain/advance-article-abstract/doi/10.1093/brain/aw
z248/5566387 by St G
eorge's U
niversity of London user on 17 Septem
ber 2019
is predicted to cause a non-synonymous substitution in
both the two major NFASC transcripts: NM_001160331.1:
c.2113C4A (p.P705T) and NM_001005388.2: c.2080C4A
(p.P694T). NM_001005388.2 is the canonical NFASC tran-
script encoding the longest protein isoform of 1241 amino
acids corresponding to Nfasc186, while NM_001160331.1
encodes the protein isoform of 1165 amino acids correspond-
ing to Nfasc155. Sanger sequencing-based segregation ana-
lysis was performed in Family 1 conﬁrming the variant.
Through GeneMatcher and SYNAPS Study Group, we iden-
tiﬁed seven additional cases, with clinical phenotypes par-
tially overlapping that of Family 1. WGS was carried out
in Proband 2 (Fig. 2A) at Genedx, Gaithersburg, USA, by
massively parallel (NextGen) sequencing on an Illumina
sequencing system with 100 bp or greater paired-end reads.
This revealed a homozygous single base deletion
(chr1:204986105delC) predicted to cause a frameshift vari-
ant in the Nfasc155 isoform NM_001160331.1: c.2816delC
(p.P939Ter) and in NFASC transcript 3 NM_015090.3:
c.2771delC (p.P924Ter). The frameshift variant is expected
to cause loss of normal protein function either through
protein truncation or nonsense-mediated mRNA decay.
WES performed for one individual of Family 3 (Fig. 2A)
detected a homozygous variant (chr1:204923488A4G), re-
sulting in a missense change in both major transcripts:
NM_001005388.2: c.388A4G (p.N130D) and NM_001160
331.1: c.298A4G (p.N124D), located within a 10Mbp
stretch of homozygosity. WES in the proband of Family 4
(Fig. 2A) revealed a homozygous variant (chr1:204951136
T4C) resulting in a missense change in both NM_0010053
88.2: c.2458T4C (p.S820P) and NM_001160331.1:c.
2491T4C (p.S831P). The index case of Family 5 (Fig. 2A)
was subjected to WES as described elsewhere (Anazi et al.,
2017). A homozygous missense variant in NFASC was iden-
tiﬁed in chr1:204939816G4C. This variant is predicted in
both major transcripts as a non-synonymous substitution:
NM_001160331.1: c.1109G4C (p.R370P) and NM_00100
5388.2: c.1076G4C (p.R359P) and it segregates with the
disease in the family (Patients 7 and 8). Family 6 was identi-
ﬁed from replication cohort screening, where WES carried
out in Probands 9 and 10 and their parents revealed a homo-
zygous missense variant in chr1:204971817T4C. This vari-
ant is predicted to be a non-synonymous substitution only
in the NF186 transcript: NFASC (NM_001005388.2:c.3230
T4C (p.V1077A) and it segregates with the disease in the
family.
Presentation of the neurofascin
disease
Table 2 summarizes the core phenotypic features of 10 in-
dividuals (aged between 3 months and 21 years), including
two patients from a Saudi Arabian family (Patients 7 and
8) described previously (Anazi et al., 2017). Figure 2B and
C illustrates the clinical features and MRI scans of affected
individuals from each family. In all patients, psychomotor
development was severely delayed (except Patients 5 and 6)
in all domains. Affected individuals did not communicate,
and none achieved purposeful hand movements or inde-
pendent ambulation. Hypotonia was present from neonatal
age in all cases. Impaired social interaction and only brief
and occasional visual contact were noticed in all affected
individuals by the ﬁrst year of age. Several patients de-
veloped restricted patterns of interests and repetitive behav-
iours and frequently exhibited hand or head stereotypies.
Moderate to severe intellectual disability was documented
in all cases. None of the affected individuals attained intel-
ligible speech. Because of muscle weakness and absent
reﬂexes, individuals from Families 1, 2, 4 and 6 underwent
detailed neurophysiological investigations as part of their
diagnostic work-up and these showed a severe reduction
in peripheral nerve conduction velocities in all cases.
Patients from Families 1 and 2 exhibited the most profound
phenotype with severe demyelinating and axonal neur-
opathy at neurophysiological investigations. Non-speciﬁc
EEG abnormalities including slow background activities
were observed in several families although affected individ-
uals had no history of seizures. Given that NFASC is ex-
pressed in various brain regions, with the highest transcript
level in the white matter region (Supplementary Fig. 7),
MRI studies of Patients 1–3, 7, 9 and 10 showed loss of
cerebral white matter, which was more severe in some af-
fected individuals (Patients 1–3) and also associated with
atrophic changes mainly involving the corpus callosum and
the brainstem (Fig. 2C). T2-weighted coronal MRI showing
enlarged lateral ventricles in Patient 1 indicative of cortical
volume loss (Fig. 2C). Interestingly, similar MRI patterns
are also presented in CASPR1-deﬁcient patients with brain-
stem and corpus callosum atrophy (Hengel et al., 2017).
Previously, cerebellar atrophy has been directly associated
with loss of NFASC in both Purkinje and basket neurons
causing abnormal basket axon collateral branching and tar-
geting to the axon initial segment, leading to extensive pin-
ceau disorganization, Purkinje neuron degeneration and
severe ataxia (Buttermore et al., 2012). Because of their
severe muscle weakness, the majority of affected individuals
had non-expressive/hypomimic face, and several craniofa-
cial dysmorphisms including bi-temporal narrowing, high
and wide nasal bridge, micrognathia, glossoptosis and
highly arched palate (Fig. 2B). The two American children
had more severe phenotype and also developed profound
sensorineural hearing loss, feeding difﬁculties requiring gas-
trostomy and respiratory difﬁculties. The younger of the
two Saudi Arabian children exhibited skeletal chest defor-
mities and generalized hypertonia (mainly affecting upper
limbs) and died at the age of 4 months, presumably due to
aspiration defects. The two French children identiﬁed from
replication cohort screening have an older age of onset
compared to the rest of the patients, and the fact that the
Nfasc155 transcript is intact while the missense variant is
only present in Nfasc186 could imply a different mode of
disease evolution.
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Molecular modelling
To examine if these disease-associated variants affect
NFASC structure and paranodal junction stability, 500 ns
molecular dynamics simulations were performed using
mutant ectodomain models based on the humanized wild-
type as a template. Rearrangements on the variant sites
showed that even though p.R370P gives no signiﬁcant ﬂuc-
tuations in terms of protein conformation and movement, a
weaker hydrophobic bond in residues 49 and 416 of the
p.N130D protein can make its conformation less regular
(Fig. 2). While the wild-type and p.R370P settle in a sta-
tionary state, p.N130D results in a slightly compressed
mutant. This is evident in their backbone root mean
squared deviation (RMSD) (Supplementary Fig. 4), which
measures the divergence of the mutant protein structure
from its initial structure over the course of the simulation
and radius of gyration (Rg), which gives an indication on
the change in size of the protein. In all cases, the most
mobile portion of the chain is residue 237 (corresponding
to residue 248 in the transcript containing the p.R370P
variant) as seen (Supplementary Fig. 4) in their root mean
squared ﬂuctuation (RMSF), which indicated how much
each residue diverges form its initial position. This arginine
residue is exposed to the aqueous solvent and part of a
larger loop, probably ﬂexible and crucial to protein dy-
namics. The RMSF further indicates that in all cases on
average the overall mobility of the backbone is not particu-
larly affected by variants.
Surface expression and protein levels
of NFASC variants
To determine the impact of genetic variants on NFASC
function, mutations were introduced in plasmids encoding
Myc-tagged human Nfasc155 or Nfasc186. In the case of
the p.P939Ter variant, the Myc-tag was inserted before the
premature stop codon in the aberrant C-terminal extension.
HEK cells were then transfected with these constructs and
the neurofascin cell surface expression was monitored by
immunocytochemistry (Fig. 3 and Supplementary Fig. 1).
To detect surface expression of NFASC isoforms, living
transfected cells were incubated with antibodies to
Nfasc155 or Nfasc186 for 20min, then cells were ﬁxed,
permeabilized and immunostained for Myc. Wild-type
Nfasc155 (Fig. 3A) and Nfasc186 (Supplementary Fig. 1
and 2) are readily expressed at the cell surface and a com-
plete co-localization is observed between the cell surface
proteins and the Myc-labelled proteins after permeabil-
ization. Most of the NFASC variants did not seem to
affect the surface expression of Nfasc155 or Nfasc186,
and a clear co-localization could be detected between sur-
face-labelled and Myc-labelled proteins (Fig. 3B–E and
Supplementary Fig. 1). Only the p.P939Ter variant strik-
ingly affected the expression of Nfasc155. This mutant pro-
tein was not detectable at the cell surface, or after Myc
labelling. To conﬁrm this observation, cells were co-
transfected with GFP then ﬁxed and stained for Myc.
When cells were co-transfected with wild-type Nfasc155,
all GFP-labelled cells also co-expressed Myc-tagged
Nfasc155 at the cell surface (Fig. 3F). By contrast, no cell
surface immunostaining was detected in cells co-transfected
with p.P939Ter (Fig. 3G). This suggested that the variant
abolished Nfasc155 expression.
To conﬁrm this observation further, we examined the
protein levels of Nfasc155 variants by western immuno-
blotting (Fig. 3H). The protein levels of p.P705T,
p.S807P and p.P939Ter mutants were found importantly
decreased compared to wild-type Nfasc155 (Fig. 3I).
Particularly, p.P939Ter was not detectable on immunoblots
even at lower molecular weight. By contrast, the p.N124D
and p.R370P variants had no signiﬁcant effect on Nfasc155
protein levels. Because p.P939Ter is a frameshift variant
inducing a premature stop codon before the transmem-
brane domain of Nfasc155, we suspected that this protein
may be released in the culture medium. We thus harvested
the cell culture medium and immunoblotted the released
fraction for Myc antibodies. No signal was detected in
the released fraction even after acetone precipitation and
concentration of the sample (data not shown), indicating
that the p.P939Ter variant abolishes Nfasc155 expression.
Nfasc155 variants inhibit the
interaction with CNTN1/CASPR1
Nfasc155 is known to interact with CASPR1 and CNTN1
at the paranodal regions of myelinated axons, and deletion
of CNTN1 or CASPR1 leads to important conduction
slowing in myelin-deﬁcient mice (Sherman et al., 2005).
Because the affected patients presented demyelinating fea-
tures, we suspected that Nfasc155 variants may alter its
interaction with these axonal partners. To test this hypoth-
esis, N2A cells were co-transfected with CNTN1, CASPR1,
and GFP, then incubated for 2 h with cells co-expressing
Nfasc155 and tandem tomato (Fig. 3). The number of cell
aggregates was then quantiﬁed. As negative control, N2A
cells expressing Nfasc155 were incubated with cells ex-
pressing GFP alone (Fig. 3). In keeping with a previous
report (Labasque et al., 2014), we found that N2A cells
expressing CNTN1/CASPR1 readily interact and form ag-
gregates with Nfasc155-expressing cells (Fig. 3J–O). By
contrast, only a minimal interaction was observed between
Nfasc155-expressing cells and GFP alone (Fig. 3P). Both
p.P705T and p.P939Ter variants abolished the interaction
between Nfasc155 and CNTN1/CASPR1, indicating that
these variants impact Nfasc155 function (Fig. 3L, O and
P). To determine whether the genetic variants may also
affect the surface expression of Nfasc186 or the interaction
of Nfasc186 with gliomedin, we tested these on a western
blot and also tested the binding of gliomedin-Fc on
Nfasc186-transfected cells. The blot showed p.N130D
had a higher expression level, while the other mutants
had a normal expression level compared to wild-type
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Figure 3 Membrane targeting of Nfasc155 variants. The homozygous Nfasc155 variants associated with a severe pathology diminish
Nfasc155 protein level. The variants p.P705T and p.P939Ter inhibit the association of CASPR1/CNTN1 with Nfasc155. (A–E) HEK cells were
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Nfasc186 (Supplementary Fig. 2). In addition, no alter-
ations on gliomedin binding were observed on any of the
Nfasc186 variants (Supplementary Fig. 1).
Immunofluorescence staining
analysis
In protein gene product 9.5/collagen IV (PGP/COLIV)
double-stained sections of both arm and leg samples from
Patient 1 (Fig. 4), cutaneous innervation appeared quite
preserved (Fig. 4B and B1 compared to A). In particular,
epidermal nerve ﬁbres as well as sudomotor and pilomotor
nerve ﬁbres appeared normally represented and regularly
distributed. Conversely, a severe loss of myelinated ﬁbres
was observed around the hair follicle as evidenced by the
simpliﬁcation of the so called ‘palisade-like’ endings origi-
nating from the few remaining myelinated ﬁbres (Fig. 4D
and D1 compared to C). Myelin staining appeared very
weak with some bright spots along the nerve course
(Fig. 4D and D1). No further myelinated ﬁbres were
observed in MBP/PGP double-stained sections. However,
small nerve fascicles were recognized in the deep dermis
in sections double-stained with Nfasc186/MBP (Fig. 4F
and F1 compared to E), panNeurofascin/MBP (Fig. 4H
and H1 compared to G) and CASPR1/MBP (Fig. 4J and
J1 compared to I). Also, in these fascicles the MBP-immu-
noreactivity appeared very weak or absent and again bright
spots were present along the nerve course. Nfasc186 immu-
noreactivity was normally expressed in the nodal region
along few proﬁles of nerve ﬁbres, as well as
panNeurofascin and CASPR1 immunoreactivity at the
paranodes. In general, we observed a severe loss of myelin-
ated ﬁbres with a preservation of the unmyelinated ones.
The abnormal immunoreactivity to MBP antibody suggests
a severe myelin involvement leading to probable nerve de-
generation. In contrast, the expression of Nfasc186 in the
nodal regions and of panNeurofascin and CASPR1 in the
paranodal regions appeared normal, although limited to
the few remaining ﬁbres. The observation of few paranodes
stained with CASPR1 as well as with panNeurofascin sug-
gests that the absence of Nfasc155 is partial in Patient 1.
In PGP/ColIV double-stained sections from Patient 3
(Fig. 5), cutaneous innervation appeared quite preserved
in the epidermis (Fig. 5A and A1) and around sweat
glands and other autonomic annexes (Fig. 5C) in all three
examined sites. Observing MBP/PGP double-stained sec-
tions from distal leg, it was evident a severe loss of mye-
linated ﬁbres surrounding the hair follicle with few
segments showing severe myelin abnormalities (Fig. 5B,
B1). In MBP/PGP double stained skin sections from the
proximal site (thigh), myelinated ﬁbres appeared more pre-
served with several myelinated segments visible around a
hair follicle (Fig. 5C and C1). Similarly, we could sample a
deﬁnitely larger amount of myelinated ﬁbres from the
ﬁngertip (Fig. 5D and D1) compared to the other two
sites, although there was an evident loss of mechanorecep-
tors and myelinated ﬁbres compared to a control case
(Fig. 5E and E1). At higher magniﬁcation, we observed
abnormalities of myelin sheet and enlargement of the
nodal gap (Supplementary Fig. 3A). In Nfasc186/MBP
images, we observed a normal expression of neuroﬁlament
staining in the node (Supplementary Fig. 3B). The nodal
structure appeared identical by visualizing the node with
the anti-panNeurofascin or the anti-Nfasc186 antibodies
(Supplementary Fig. 3C). CASPR1 immunoreactivity
was completely absent in the paranodal regions
(Supplementary Fig. 3D). Additionally, an apparently
normal distribution of voltage-gated sodium (Nav) channels
appeared in MBP/Nav double-staining images in several
nodes that appeared larger, however less compacted than
in the control skin (Supplementary Fig. 3F). Moreover, a
granular distribution of Nav was evident along the axonal
proﬁles of large ﬁbres devoid of myelin (arrows in
Supplementary Fig. 3E) that suggested a Nav remodelling
Figure 3 Continued
transfected with Myc-tagged Nfasc155 variants and surface Nfasc155 was monitored by incubating the live cells with anti-Nfasc155 IgG (red) prior
to fixation and permeabilization. Nfasc155 was then revealed using an anti-Myc antibody (green). Wild-type Nfasc155, but also the variants
p.N124D, p.R370P, p.P705T and p.S831P were readily targeted at the cell surface, and did not show signs of intracellular retention. (F–G) HEK
cells were co-transfected with GFP (green) and either wild-type Nfasc155 or p.P939Ter variant, then cells were immunostained for Myc (red). In
contrast to wild-type Nfasc155, p.P939Ter was not detectable, indicating that this mutation strongly affects Nfasc155 expression. Nuclei are
stained DAPI (blue). Scale bar = 10 mm. (H) Western blot analysis of HEK cells transfected with Nfasc155 variants and revealed with anti-Myc
antibodies or anti-a-tubulin antibodies as loading control. (I) Protein expression levels were analysed by normalizing the signals to the corres-
ponding -tubulin signal, then to wild-type Nfasc155 in four independent experiments. The expression levels of p.P705T, p.S831P and p.P939Ter
variants were significantly decreased compared to wild-type Nfasc155 (Mann-Whitney test). *P5 0.01; **P5 0.005; ***P5 0.001; by unpaired
two-tailed Student’s t-tests for two samples of equal variance and by one-way ANOVA followed by Bonferroni’s post hoc tests. Bars represent
mean and SEM. Molecular weight markers are shown on the left (in kDa). N.S. = not significant. (J–O) N2A cells were transfected with GFP
(green) in combination with CNTN1 and CASPR1 and were incubated for 2 h with cells transfected with tandem tomato (magenta) and wild-type
Nfasc155 (J), p.P705T (M) or pP939Ter (O). As negative control, N2A cells transfected with Nfasc155 (magenta) were incubated with cells
transfected with GFP. (P) The numbers of green and magenta cell aggregates (dashed line circles in J–O) per visualization field were quantified in
each condition (n = 4 experiments for each condition). p.R370P, p.P705T, p.S831P and p.P939Ter mutations significantly decreased aggregate
formation. ***P5 0.001 by unpaired two-tailed Student’s t-tests and by one-way ANOVA followed by Bonferroni’s post hoc tests. Bars represent
mean and SEM. Scale bar = 20 mm.
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Figure 4 Severe involvement of peripheral myelinated fibres and partial disruption of Nfasc155 at the paranode in Patient 1.
Confocal images of cutaneous innervation from hairy skin (leg and arm) of the patient compared to a control showing well preserved unmye-
linated fibres in the epidermis and dermis (B and B1 compared to A), severe loss of myelinated fibres around a hair follicle and the few remaining
ones presenting a very weak MBP (red) immunoreactivity (D, D1 arrowheads compared to C), in a nerve bundle with few remaining myelinated
fibres presenting a very faint staining with MBP antibody presence of nodes marked with Nfasc186 (green) (F and F1 compared to E), paranodes
marked with panNeurofascin (green) (H, H1 arrowheads compared to G) and paranodes marked with CASPR (green) (J and J1 arrowheads
compared to I). Scale bar = 100 mm in A, B, B1; 50mm in C, D, D1; 30mm in F–J1.
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after demyelinating phenomena. Those data indicate that
the frameshift variant in Patient 3, which induces a com-
plete lack of Nfasc155 expression, does not provoke a
complete disruption of the node. There was, however, a
severe alteration of the paranode as showed by the com-
plete absence of the CASPR1, the physiological ligand of
Nfasc155, and a severe effect on myelination and/or main-
tenance of myelin and survival of large ﬁbres, which ap-
pears to be length-dependent. Interestingly, small ﬁbres,
both somatic and autonomic appeared less affected by the
variant in both patients.
NFASC cell-specific expression and
co-expression analysis
We ﬁrst explored the expression of NFASC in the central
and peripheral nervous system using publicly available cell-
speciﬁc transcriptomic data (Zhang et al., 2016; Zeisel
et al., 2018). In keeping with the known function of
NFASC, RNA sequencing of puriﬁed cell types derived
from human cortex demonstrated that NFASC was most
highly expressed in oligodendrocytes though there was also
evidence of expression in neurons and, to a lesser extent,
astrocytes and endothelial cells (Supplementary Fig. 6).
We also found that NFASC expression was highest in
newly formed oligodendrocytes rather than myelin-forming
or mature oligodendrocytes. Next, we investigated the
function of NFASC using gene co-expression analysis
to construct networks for all 13 human brain regions
sampled by the Genotype Tissue Expression Consortium
(Supplementary Table 2) (Human Genomics, 2015). In
the anterior cingulate cortex, NFASC was located with
high conﬁdence (module membership = 0.74) within a co-
expression module, which is enriched for genes involved in
synaptic transmission (GO:0099536, chemical synaptic
transmission FDR-corrected P-value = 6.68  1010) and
expressed speciﬁcally in neurons (neuron module in cortex,
FDR-corrected P-value = 6.0  1072). Furthermore, this
module was enriched for genes known to be associated
with monogenic forms of intellectual disability (FDR-cor-
rected P-value 2.12  103, Supplementary Fig. 5).
Discussion
Homozygous variants in NFASC lead to a neurodevelop-
mental disorder that includes—in some families—a chronic
demyelinating neuropathy. Radiological features in some
NFASC individuals included central white matter loss
and atrophy of the corpus callosum and the brainstem
(Fig. 2C). As part of their phenotype, several affected indi-
viduals also exhibited features of central demyelination and
clinical and neurophysiological evidences of chronic periph-
eral demyelinating neuropathy associated with severe re-
duction in nerve conduction velocities and prolonged
motor latencies (Table 2 and Supplementary Table 1).
Interestingly, these patients have a similar phenotype to
patients with CNTNAP1/CASPR1 mutations; however,
without any epilepsy, which has been reported in
CASPR1-mutated patients. It is possible that a different
Figure 5 Severe involvement of peripheral myelinated
axons in Patient 3 with complete lack of Nfasc155 expres-
sion at paranodes. Confocal images of cutaneous innervation
from hairy and glabrous skin (thigh and fingertip) of the patient
compared to a control showing quite preserved unmyelinated fibres
in the epidermis (A and A1) and around autonomic annexes (see
arrector pili muscle, arrowheads in C); severe loss of myelinated
fibres with evidence in a nerve fascicle of few segments with severe
myelin abnormalities in the distal site (leg) (B and B1); more pre-
served myelinated fibres with evidence around a hair follicle of
several myelinated fibres showing loss of myelin in their distal seg-
ments in the more proximal site (thigh) (C, arrowheads in C1); loss
of mechanoreceptors and myelinated fibres (compared to the
control in E and E1) and morphological abnormalities of myelinated
fibres with tracts of demyelination in the fingertip (D, arrowheads in
D1) (compared to the control in E and E1). Scale bar = 100 mm in
A, A1, C, C1, D, D1, E, E1 and 30mm in B and B1.
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role is played by CASPR1 and NFASC in neuron excitability
at CNS level (Laquerriere et al., 2014; Hengel et al., 2017).
Immunoglobulin G subclass 4 (IgG4) antibodies to
Nfasc155 and Nfasc186 have been identiﬁed in 3–18%
of patients with chronic inﬂammatory demyelinating poly-
radiculoneuropathy (Querol et al., 2014; Ogata et al.,
2015; Delmont et al., 2017). Nfasc155 IgG4 antibodies
are associated with speciﬁc clinical features including an
early onset of the CIDP disease, a distal predominant pat-
tern of weakness, and the presence of sensory ataxia and
tremor. A cerebellar origin of the tremor has been hypothe-
sized in some cases (Devaux, 2014; Querol et al., 2014;
Ogata et al., 2015). Also, and most importantly to the
present study, up to 8% of CIDP patients with IgG4
Nfasc155 showed evidence of CNS demyelination
(Devaux et al., 2016) and anti-Nfasc155 antibodies were
identiﬁed at high frequency in Japanese patients with com-
bined central and peripheral demyelination (Kawamura
et al., 2013), although this was not replicated in the
Caucasian population (Cortese et al., 2016).
The majority of NFASC mutated individuals identiﬁed in
this study were found with homozygous missense variants
affecting highly conserved residues within the Ig-like do-
mains or in the ﬁbronectin type III domains of the neuro-
fascin protein (Fig. 2E). One family (Family 2) was
identiﬁed with a homozygous frameshift deletion predicted
to result in a premature truncation of the protein. Among
our patients, affected individuals from Family 2 carrying
the p.P939Ter frameshift deletion exhibited the more
severe phenotype with marked neurodevelopmental impair-
ment and profound muscle weakness associated with severe
reduction of conduction velocities on neurophysiological
investigations. Given the history of consanguineous mar-
riages in these families, other recessive variants may also
have contributed to the clinical phenotype, as in Proband 8
from Family 5 who died prematurely, presumably because
of aspiration due to respiratory difﬁculties.
The results from our functional analyses indicate abnor-
mal Nfasc155 interaction with CNTN1 and CASPR1 as an
important disease mechanism in the NFASC-related genetic
disease. In addition, loss of Nfasc155 surface expression
may also be implicated in the phenotype observed in the
affected individuals. Immunoﬂuorescence studies on
Patients 1 and 3 detected a severe loss of myelinated
ﬁbres with a preservation of the unmyelinated ones, and
while the expression of Nfasc186 in the nodal regions ap-
peared normal in both patients, the absence of Nfasc155 in
the paranodal region was only partial in Patient 1. Western
blot showed that the protein levels of several Nfasc155
mutants including p.P705T and p.P939Ter were import-
antly decreased compared to wild-type Nfasc155. These
biochemical ﬁndings support the morphological ﬁndings
and indicate that there may be an incomplete derangement
of the paranodal region in some patients due to a reduction
of glial Nfasc155. This could explain the relatively milder
phenotype of Patients 6 and 7 as well as that of the recently
described patient with a similar neurodevelopmental syn-
drome (Smigiel et al., 2018).
Of interest, in cell-speciﬁc in silico studies, NFASC is
mostly expressed in newly formed oligodendrocytes, and
found to be enriched for genes associated with monogenic
forms of intellectual disability. Given recent evidence that
the generation of new myelin segments is an important
form of plasticity that can be used to modify the properties
of circuits in the CNS (McKenzie et al., 2014; Xiao et al.,
2016), these observations may be signiﬁcant and provide
some explanation for the neurodevelopmental features of
individuals carrying biallelic NFASC variants. We could
further speculate that in at least some brain regions
NFASC may play an important role in synaptic transmis-
sion and that this potentially might explain how biallelic
variants in the gene result in central neurological features.
Interestingly, homozygous NFASC-null mice are born
with a normal appearance but die suddenly 7 days after
birth when the postnatal transition to saltatory conduction
is occurring in the CNS and PNS. Over-expression of either
of the two neuronal isoforms (Nfasc186 or Nfasc140) helps
them survive into adulthood but mice are ataxic, presum-
ably because they do not have intact paranodal axoglial
junctions in their myelinated nerves (Sherman et al., 2005).
Recently, a homozygous splice-site variant in NFASC was
identiﬁed in an individual with neurodevelopmental impair-
ment, hypotonia and areﬂexia (Farwell Hagman et al.,
2017). Another family was found within a large genetic
study carrying a homozygous NFASC variant associated
spinal muscular atrophy (Smigiel et al., 2018) and a homo-
zygous missense mutation leads to signiﬁcant loss of
NFASC protein in induced pluripotent stem cell-derived
neurons from affected subjects (Monfrini et al., 2019).
Despite these reports, the implication of NFASC muta-
tions in the development of human diseases remains to be
fully elucidated and warrants further investigations on a
larger scale. Our results strongly establish the association
of biallelic NFASC variants in the complex central and
peripheral nervous system involvement presented by the
10 affected individuals described in this study. The notion
of a genetic NFASC disease further delineates an emerging
spectrum of human neurological disorders caused by vari-
ants in cell adhesion and ankyrin-binding genes involved in
neurite extension, axonal guidance, synaptogenesis, myelin-
ation and neuron-glial cell interactions.
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